Education
About Us
Working with TipRanks
Follow Us
Caribou Biosciences, Inc. (CRBU)
:CRBU
CRBU Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $3.00
Previous CloseN/A
Volume598.80K
Average Volume (3M)2.02M
Market Cap
$189.73M
Enterprise Value-$97.62M
Total Cash (Recent Filing)$208.47M
Total Debt (Recent Filing)$26.22M
Price to Earnings (P/E)―
Beta2.65
Next Earnings
Aug 12, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding93,004,600
10 Day Avg. Volume1,876,889
30 Day Avg. Volume2,023,414
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.51
Enterprise Value/Revenue-9.84
Enterprise Value/Gross Profit-12.39
Enterprise Value/Ebitda0.61
Forecast
1Y Price Target
$5.75Price Target Upside173.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company ended the period with $212.5 million in cash and equivalents, expected to fund upcoming developments.
Market PositionAnalyst continues to consider Caribou undervalued and believes that the company's current situation involves a much more favorable position from which to weather equity capital markets volatility.
Strategic FocusCaribou announced a strategic reprioritization to focus on oncology programs for CB-010 in large B cell lymphoma (LBCL) and CB-011 in multiple myeloma (MM) with a workforce (~32%) and cost reduction.
Bears Say
Approval ProbabilityThere is a probability of only 30% for the approval of CB-010 and 20% for CB-011.
Clinical RisksRisks include negative clinical results with the company's lead assets and delays in advancing these candidates into registrational programs.
Pipeline ValueThe discontinuation of CB-010 in lupus, CB-012 in AML, and preclinical research does reduce the value from the pipeline.
Caribou Biosciences News
CRBU FAQ
What was Caribou Biosciences, Inc.’s price range in the past 12 months?
Caribou Biosciences, Inc. lowest stock price was $0.66 and its highest was $3.00 in the past 12 months.
What is Caribou Biosciences, Inc.’s market cap?
Caribou Biosciences, Inc.’s market cap is $189.73M.
When is Caribou Biosciences, Inc.’s upcoming earnings report date?
Caribou Biosciences, Inc.’s upcoming earnings report date is Aug 12, 2025 which is in 4 days.
How were Caribou Biosciences, Inc.’s earnings last quarter?
Caribou Biosciences, Inc. released its earnings results on May 08, 2025. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.434 by $0.004.
Is Caribou Biosciences, Inc. overvalued?
According to Wall Street analysts Caribou Biosciences, Inc.’s price is currently Undervalued.
Does Caribou Biosciences, Inc. pay dividends?
Caribou Biosciences, Inc. does not currently pay dividends.
What is Caribou Biosciences, Inc.’s EPS estimate?
Caribou Biosciences, Inc.’s EPS estimate is -0.4.
How many shares outstanding does Caribou Biosciences, Inc. have?
Caribou Biosciences, Inc. has 93,004,600 shares outstanding.
What happened to Caribou Biosciences, Inc.’s price movement after its last earnings report?
Caribou Biosciences, Inc. reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.434. Following the earnings report the stock price went down -2.532%.
Which hedge fund is a major shareholder of Caribou Biosciences, Inc.?
Currently, no hedge funds are holding shares in CRBU
Caribou Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.75 (173.81% Upside)
$5.75 (173.81% Upside)
Blogger Sentiment
Bullish
CRBU Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 74.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.83%
12-Months-Change
Fundamentals
Return on Equity
-52.76%
Trailing 12-Months
Asset Growth
-32.73%
Trailing 12-Months
Company Description
Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
CRBU Stock 12 Month Forecast
Average Price Target
$5.75
▲(173.81% Upside)
Technical Analysis
Ownership Overview
8.16% Insiders
9.56% Mutual Funds
0.05% Other Institutional Investors
74.53% Public Companies and
Individual Investors